Answers are grounded in this paper and cite their sources.
Background Bispecific antibody-drug conjugates (BsADCs) represent a promising therapeutic strategy to overcome single-target resistance. Here, we developed a dual-targeting BsADC that simultaneously recognizes CD44v6 and VEGFR2. Methods Spatial configurations were optimized in CHO expression systems. In vitro binding affinities and cytotoxicity were evaluated alongside in vivo anti-tumor efficacy and systemic toxicity in xenograft models. Results The variant BIWA8-(G4S) 2 -DC101-scFv exhibited high stability and an SEC purity of 84.6%. The construct retained antigen-binding affinity and mediated dose-dependent cytotoxicity in vitro . In mouse xenograft models, the dual-targeting BsADC showed potential anti-tumor activity compared to single-target controls, with no overt body weight loss or observable physical toxicity detected during treatment. Conclusion These findings suggest that the CD44v6/VEGFR2-targeting BsADC represents a potential candidate for targeted cancer therapy. Limitations High-resolution LC-MS characterization for absolute DAR distribution and long-term toxicity evaluations in non-human primates were not performed in this preliminary work.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: